After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer—the first time anyone has linked the disease’s reemergence to specific genetic anomalies. The discovery, co-lead by William L. Carroll, MD, director of NYU Langone Medical Center’s Cancer Institute, is reported in a study published online February 3, 2013, in Nature Genetics.
